Exenatide acetate (141732-76-5) video
Exenatide acetate (141732-76-5)
Exenatide (i, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1).
Exenatide is an incretin mimetic, which has glucoregulatory effects. While it is has blood-sugar lowering actions alone, it can also be combined with other medications such as pioglitazone, metformin, sulfonylureas, and/or insulin to improve glucose control. The approved use of exenatide is with either sulfonylureas, metformin and thiazolinediones. The medication is injected twice per day using a pre-filled pen device. Typical human responses to exenatide plus eating include improvements in the initial rapid release of endogenous insulin, suppression of glucagon release by the pancreas, regulation of gastric empyting and reduced appetite; all behaviors more typical of individuals without blood sugar control problems. Exenatide is self-regulating in that in lowers blood sugar when levels are elevated but does not continue to lower blood sugar when levels return to normal, unlike with sulfonylureas or insulins.
Exenatide acetate (141732-76-5) Specifications
|Product Name||Exenatide acetate|
|Chemical Name||EXENATIDE ACETATE; 141732-76-5; C184H282N50O60S.C2H4O2; Exendin-4 (Acetate); H659;|
|Molecular Weight||4246.682 g/mol|
|Monoisotopic Mass||4244.048 g/mol|
|Melting Point||>209°C (dec.)|
|Biological Half-Life||2.4 h|
|Color||White to Off-White Solid|
|Solubility||Acetonitrile (Slightly), Water (Slightly)|
|Application||A 39-amino acid peptide originally isolated from the salivary glands of the Gila monster (Heloderma suspectum), differs from exendin-3 only in two positions close to the N-terminus. Application of exenatide causes an increase in acinar cAMP without stimulating amylase release. As an incretin mimetic, exenatide acts as agonist of the glucagon-like peptide-1 (GLP-1) receptor. As GLP-1, though with prolonged activity, exenatide augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, exenatide has found use as a medication of diabetes II.|